R&D channel feed

Bay­er ex­pands Keren­dia heart fail­ure pro­gram to 15,000 pa­tients as it plans to start three Phase III tri­als

Last year
Pharma

Roche says Ale­cen­sa helps keep ALK-pos­i­tive lung can­cer at bay af­ter surgery as it looks to ex­pand la­bel

Last year

BioN­Tech, Du­al­i­ty­Bio steer ADC in­to PhI­II, with aim to com­pete in HER2-low sub­group with En­her­tu

Last year

Bavar­i­an Nordic aban­dons Covid boost­er af­ter da­ta show it's not as ef­fec­tive against new vari­ants

Last year
Coronavirus

Zevra beefs up rare dis­ease port­fo­lio via $91M ac­qui­si­tion of Ac­er Ther­a­peu­tics

Last year
Deals

As Revlim­id sales fall, Bris­tol My­ers turns to its next mul­ti­ple myelo­ma pill that's a mol­e­c­u­lar glue

Last year

Sage shrinks work­force by 40% in light of ma­jor de­pres­sion drug re­jec­tion 

Last year
People

FDA+ roundup: FDA is­sues fi­nal guid­ance on use of re­al-world ev­i­dence

Last year
Pharma
FDA+

Af­ter de­lay, Abeona aims for fall FDA sub­mis­sion for rare skin con­di­tion cell ther­a­py

Last year
FDA+

PhI­II fail in Duchenne casts shad­ow over Fi­bro­Gen's top an­ti-fi­brot­ic pro­gram

Last year

Ex­clu­sive: 10x Ge­nomics CEO touts ‘in­cred­i­ble trac­tion’ with newest launch, ship­ping over 100 spa­tial bi­ol­o­gy an­a­lyz­ers

Last year

Apel­lis trims staff, shrinks R&D plans to save mon­ey in face of loom­ing com­pe­ti­tion in oph­thal­mol­o­gy

Last year
People
Pharma

No­var­tis nix­es PhII TGFß an­ti­body — and one-time 'wild card' — af­ter ben­e­fit-risk as­sess­ment

Last year

Am­gen says RNA heart drug has long-last­ing ef­fect as it races No­var­tis; Eli Lil­ly takes pill ap­proach to same tar­get: #ESC23

Last year

Novo­cure fails PhI­II in plat­inum-re­sis­tant ovar­i­an can­cer

Last year

No­var­tis’ Leqvio cuts LDL lev­els by 50% over three years: #ESC23

Last year

Up­dat­ed: Bridge­Bio's AT­TR-CM drug bests place­bo in de­tailed PhI­II da­ta, bol­ster­ing plans for NDA

Last year

Blue­Rock, Bay­er's stem cell group, de­tails glimpses of ef­fi­ca­cy in Parkin­son's dis­ease ther­a­py

Last year

Mer­ck and Ei­sai to stop Keytru­da plus Lenvi­ma tri­al in head and neck can­cer af­ter dis­ap­point­ing in­ter­im re­sults

Last year

Once again, Novo's semaglu­tide shows car­dio­vas­cu­lar ben­e­fit, weight loss — this time in adults with heart fail­ure

Last year

Af­ter first-line ap­proval in DL­B­CL, de­bate con­tin­ues around ben­e­fit from Roche's ADC Po­livy

Last year

Ab­b­Vie drops two ear­ly-stage AD­Cs, in­clud­ing Pfiz­er-part­nered on­col­o­gy pro­gram

Last year
Pharma

KRAS late­com­er Roche draws cau­tious com­par­isons to Am­gen, Mi­rati in ear­ly da­ta

Last year

In PhI­II da­ta, Eli Lil­ly’s Retev­mo meets pri­ma­ry end­point of im­prov­ing pro­gres­sion-free sur­vival

Last year
Pharma
First page Previous page 73747576777879 Next page Last page
A service from the Financial Times